Position Paper Release, Acquisition Agreement, Quarterly Earnings, Technical Updates, and New Medicare Plans – Research Reports on Intercontinental, Marsh & McLennan, Waters, Teva and WellPoint

NEW YORK, October 27, 2014 /PRNewswire/ --

Today, Analysts Review released its research reports regarding Intercontinental Exchange, Inc. (NYSE: ICE), Marsh & McLennan Companies, Inc. (NYSE: MMC), Waters Corporation (NYSE: WAT), Teva Pharmaceutical Industries Limited (NYSE: TEVA) and WellPoint Inc. (NYSE: WLP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7440-100free.

Intercontinental Exchange, Inc. Research Reports 

On October 20, 2014, Intercontinental Exchange, Inc. (Intercontinental Exchange) announced that ICE Benchmark Administration (IBA) has published a Position Paper on the evolution of ICE LIBOR. In its paper, IBA has set out its key findings so far on the administration of LIBOR; a summary of recent improvements to the LIBOR administration process; and proposals for consultation on further enhancements to the LIBOR submission process. Finbarr Hutcheson, President of IBA, said, "At IBA, we are seeking to make LIBOR ever more robust by creating a methodology that can keep pace with today's fast moving markets. We believe that IBA's approach to evolving benchmarks will benefit LIBOR's many and diverse stakeholders." IBA has sought feedback on its proposals from all LIBOR stakeholders. The full research reports on Intercontinental are available to download free of charge at:

http://www.analystsreview.com/Oct-27-2014/ICE/report.pdf

Marsh & McLennan Companies, Inc. Research Reports 

On October 20, 2014, Marsh & McLennan Companies, Inc.'s wholly-owned subsidiary Marsh announced that it has signed a definitive agreement to acquire Torrent Technologies, Inc., a leading service provider to Write Your Own (WYO) insurers participating in the National Flood Insurance Program (NFIP). As per the deal between the duos, Torrent's nearly 100 employees will combine with Marsh's existing flood insurance specialists to create a Flood Center of Excellence, which will offer a comprehensive suite of flood insurance products and services. Travis Pine, Chairman and CEO of Torrent, said, "We have always been impressed with Marsh's flood experience and strong commitment to the NFIP. We couldn't be happier to join the firm and are excited that this combination will provide our clients the most advanced and holistic suite of NFIP-related capabilities available in the market." The full research reports on Marsh & McLennan are available to download free of charge at:

http://www.analystsreview.com/Oct-27-2014/MMC/report.pdf

Waters Corporation Research Reports
On October 21, 2014, Waters Corporation (Waters) announced its Q3 2014 financial results. The analytical instrument manufacturer reported net sales for the quarter at $493.2 million, up 7.8% YoY. Waters' net income in the quarter increased to $113.5 million, or $1.34 per diluted share, from $98.0 million or $1.14 per diluted share in the year ago period. On a non-GAAP basis, the Company's Q3 2014 EPS increased to $1.38, beating the Zacks Consensus Estimate of $1.28 by 10 cents. Douglas A. Berthiaume, Chairman, President, and CEO, said, "Broad-based demand from pharmaceutical customers highlighted our strong organic revenue growth in the third quarter. In addition, improvements in margins contributed to solid mid-teens EPS growth." Following the results, shares of the Company rallied 9.87% to close at $107.17 on October 21, 2014. The full research reports on Waters are available to download free of charge at:

http://www.analystsreview.com/Oct-27-2014/WAT/report.pdf

Teva Pharmaceutical Industries Limited Research Reports 

On October 21, 2014, the stock (ADR) of Teva Pharmaceutical Industries Limited (Teva) gained 3.04% to end the trading session at $53.26. During the session, Teva's stock opened at $52.19, and fluctuated in the range of $51.72 - $53.30, with a total of 4.40 million ADRs changing hands. The rise in Teva's ADRs was in-line with the broad market rally in U.S., with the tech-heavy NASDAQ Composite gaining over 2% on back of better-than-expected quarterly numbers reported by technology giants like Apple and Texas Instruments. Over the last one month, the Company's stock has increased by 4.33%, compared to the S&P 500 index which fell 2.66% during the same period. The full research reports on Teva are available to download free of charge at:

http://www.analystsreview.com/Oct-27-2014/TEVA/report.pdf

WellPoint Inc. Research Reports 

On October 14, 2014, WellPoint Inc. (WellPoint) reported that its affiliates will offer a wide range of options during the traditional Medicare Advantage and Part D enrollment season, which begins on October 15, 2014 with the opening of the Annual Election Period (AEP) and closes December 7, 2014. During this period, WellPoint affiliates in 21 states will offer a host of plans, including Medicare Advantage (MA), Prescription Drug Plans (PDPs), Medicare Advantage Prescription Drug Plans (MAPD), group plans and Medicare Supplement products. "This year, in particular, we've focused on developing products that are a good value and easy to use with benefits that help members get and stay healthy," said Marc Russo, President of Medicare programs for WellPoint. The full research reports on WellPoint are available to download free of charge at:

http://www.analystsreview.com/Oct-27-2014/WLP/report.pdf

About Analysts Review

We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.

===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

http://www.AnalystsReview.com 

SOURCE Analysts Review